Ultragenyx Email Format

Biotechnology Research
1,001-2,500 employees
Novato, CA, USA

Ultragenyx is a biotechnology company focused on developing and commercializing novel therapies for rare and ultrarare genetic diseases with high unmet medical needs.

Find contacts at Ultragenyx

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

firstinitiallast@ultragenyx.com

Company Overview

Industry
Biotechnology Research
Founded
2010
Headquarters
Novato, CA, USA
Revenue
$500M-$1B
FUNDING Stage
Public
Key Executives
Emil D. Kakkis (Founder, President and Chief Executive Officer), Howard Horn (Chief Financial Officer and Executive Vice President, Corporate Strategy), Dennis Huang (Chief Technical Operations Officer and Executive Vice President, Gene Therapy Research and Development)

Tech Stack

Veeva Vault

Quality Management / Life Sciences Cloud

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Ultragenyx?

Ultragenyx uses the firstinitiallast format on ultragenyx.com, so Jane Smith would be jsmith@ultragenyx.com.

What approved products does Ultragenyx currently sell?

Ultragenyx has four approved therapies: Crysvita for X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii for MPS VII, Dojolvi for long-chain fatty acid oxidation disorders, and Evkeeza for homozygous familial hypercholesterolemia, which it markets outside the U.S.

Who founded Ultragenyx and when was the company started?

Emil D. Kakkis, M.D., Ph.D., founded Ultragenyx in 2010 and continues to serve as its President and Chief Executive Officer. He is also President of the EveryLife Foundation for Rare Diseases.

How does Ultragenyx's gene therapy research and development program work?

Ultragenyx runs a dedicated gene therapy research and development program led by Dennis Huang, Chief Technical Operations Officer, using AAV gene therapy as one of four drug modalities the company applies to rare and ultrarare genetic diseases.

Can Clay help me find and verify contact details for Ultragenyx employees?

Yes, Clay can enrich and verify email addresses for Ultragenyx's 1517 employees by applying the firstinitiallast format on ultragenyx.com, making it straightforward to build a reliable outreach list for the company's teams.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles